menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'Patient Reported Outcomes' ×
Susan Abedi
BrianKelly
Data integration is key to unlocking the productivity puzzle in the world of registries.
Read More
StellaBlackburn
What we learned from conducting an observational study of pregnant women throughout their pregnancies.
Read More
Jennifer Christian
How to improve collection of patient reported data, and how it can increase the value of new treatments.
Read More
Jean Paty
Why the industry needs to translate complex clinical results into value-based terms that everyone understands.
Read More
Jean Paty
How patient reported outcomes will define clinical trials of the future.
Read More
Jean Paty
Wrapping up Patient Safety Awareness Week, Jean Paty explains how to incorporate the voice of the patient into clinical development.
Read More
Montse Casamayor
Patient reported outcomes (PRO) have become an increasingly important part of the oncology drug approval process. End of 2009, the US Food and Drug Administration (FDA) issued a formal guidance to describe how PRO instruments will be reviewed and evaluated with respect to claims in approved medical product labeling; and four years later EMA produced a reflection paper on the use of PRO measures in oncology studies. Regulators clearly value this data as part of their drug assessment process, but what about after the drug is approved? PRO data provides valuable insight into the quality and efficacy of these drugs, but there has been little research to determine whether payers and providers use this information in the context of decision-making for cancer treatments. To provide some...
Read More
PaulSutton
The annual NHS drug bill stands at £13.8bn per annum1, and NICE has estimated that £4bn of medicines are not used correctly2. With the successful treatment of a disease depending on consistent use of medicines as prescribed, non-adherence is a pertinent issue for all healthcare stakeholders. Patients who do not adhere to their treatment are also at risk of increased hospitalization, resulting in further unnecessary costs to the healthcare economy.  We have spoken in previous blogs about the value relationship that needs to exist between biopharma and the NHS (both payers and providers), and the need for biopharma to help those payers and providers develop confidence to use a new product. Biopharma needs to address two related, but different, concerns: Biopharma will more...
Read More
NancyDreyer
Real-world research has gained increasing prominence in the clinical trial research process, it is important to keep in mind the complementary information and related benefits that these data bring to patients, physicians and the pharmaceutical industry.  Patient registries in particular are a useful approach to getting systematic information about the patient experience in dealing with diseases and the health care system. Getting perspective on that patient experience, including how they respond to various treatments, is critically important to helping to shape meaningful clinical trials, and to put the results of those clinical trials in context. For example, how many patients in the “real world” are like those tested in the clinical trial, and for those who are different, in what ways...
Read More